These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial. Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247 [TBL] [Abstract][Full Text] [Related]
24. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Martin BG; Ratner PH; Hampel FC; Andrews CP; Toler T; Wu W; Faris MA; Philpot EE Allergy Asthma Proc; 2007; 28(2):216-25. PubMed ID: 17479608 [TBL] [Abstract][Full Text] [Related]
25. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Tripathy I; Levy A; Ratner P; Clements D; Wu W; Philpot E Pediatr Allergy Immunol; 2009 May; 20(3):287-94. PubMed ID: 19175889 [TBL] [Abstract][Full Text] [Related]
26. Once-Daily Fluticasone Furoate/Vilanterol Versus Once-Daily Fluticasone Furoate in Asthma Patients Aged 5-17 Years. Bareille P; Forth R; Imber V; Bondarenko I; Michaud A; Majorek-Olechowska B Ann Allergy Asthma Immunol; 2024 Jun; ():. PubMed ID: 38936466 [TBL] [Abstract][Full Text] [Related]
27. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. Li JT; Goldstein MF; Gross GN; Noonan MJ; Weisberg S; Edwards L; Reed KD; Rogenes PR J Allergy Clin Immunol; 1999 Apr; 103(4):622-9. PubMed ID: 10200011 [TBL] [Abstract][Full Text] [Related]
28. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P; Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075 [TBL] [Abstract][Full Text] [Related]
29. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial. Kemp JP; Osur S; Shrewsbury SB; Herje NE; Duke SP; Harding SM; Faulkner K; Crim CC Mayo Clin Proc; 2004 Apr; 79(4):458-66. PubMed ID: 15065610 [TBL] [Abstract][Full Text] [Related]
30. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Woodcock A; Bateman ED; Busse WW; Lötvall J; Snowise NG; Forth R; Jacques L; Haumann B; Bleecker ER Respir Res; 2011 Oct; 12(1):132. PubMed ID: 21977941 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581 [TBL] [Abstract][Full Text] [Related]
33. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Casale TB; Nelson HS; Stricker WE; Raff H; Newman KB Ann Allergy Asthma Immunol; 2001 Nov; 87(5):379-85. PubMed ID: 11730179 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Lötvall J; Bleecker ER; Busse WW; O'Byrne PM; Woodcock A; Kerwin EM; Stone S; Forth R; Jacques L; Bateman ED Respir Med; 2014 Jan; 108(1):41-9. PubMed ID: 24295556 [TBL] [Abstract][Full Text] [Related]
35. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma. Kempsford RD; Bal J; Baines A; Renaux J; Ravindranath R; Thomas PS Respir Med; 2016 Mar; 112():18-24. PubMed ID: 26823210 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Woodcock A; Vestbo J; Bakerly ND; New J; Gibson JM; McCorkindale S; Jones R; Collier S; Lay-Flurrie J; Frith L; Jacques L; Fletcher JL; Harvey C; Svedsater H; Leather D; Lancet; 2017 Nov; 390(10109):2247-2255. PubMed ID: 28903864 [TBL] [Abstract][Full Text] [Related]
38. Fluticasone furoate/vilanterol: a review of its use in patients with asthma. Syed YY Drugs; 2015 Mar; 75(4):407-18. PubMed ID: 25648266 [TBL] [Abstract][Full Text] [Related]
39. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. Crim C; Gotfried M; Spangenthal S; Watkins M; Emmett A; Crawford C; Baidoo C; Castro-Santamaria R BMC Pulm Med; 2020 May; 20(1):119. PubMed ID: 32366249 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]